Peptide Index
Every peptide,
explained simply.
Peptide Index
- 17
- Compound profiles
- 4
- Evidence levels
- Live
- Trials & studies
How to read this: every card shows the strongest evidence that exists. Animal and lab results are early clues, not proven benefits in people. Only compounds marked “Approved medicine” are approved, and only for the uses listed.
📦 My peptide supply kit
The supplies I use, in one Amazon list. Only use them for medicines your clinician prescribes. Never share or reuse needles, and put used ones in a sharps container.
Metabolic
Retatrutide
InvestigationalAn experimental once-a-week injection that acts on three appetite and metabolism hormones at the same time.
- Studied for
- Obesity, type 2 diabetes, knee arthritis and heart disease with obesity. In the 2026 TRIUMPH-1 phase 3 trial, the top dose averaged 25% weight loss at 80 weeks.
- Limits of the evidence
- Not approved; Lilly plans to file in early 2027. Long-term safety is unknown. Outside trials, products are unregulated.
- Approval
- Investigational; phase 3 trials reported in 2026, FDA filing planned for early 2027
Uses, latest studies & pairings
Typically used for
- Obesity: the main use being tested, in the TRIUMPH phase 3 program.
- Type 2 diabetes, knee osteoarthritis pain with obesity, heart disease with obesity, fatty liver and kidney disease (in trials).
- It is also sold online as a “research chemical” for weight loss. Those products are unregulated and their contents are unverified.
Commonly paired with
- Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
- Not combined with other GLP-1 medicines: they work on the same receptors, so stacking adds side effects, not safety.
- Diarrhea and nausea were the most common side effects, so fluids and electrolytes matter while the dose is being raised.
Latest studies & news
- Jul 2026
TRIUMPH-2 (type 2 diabetes): about 13–21% weight loss at 80 weeks, with HbA1c down by up to 1.6 points. TRIUMPH-3 (obesity with heart disease): up to 22.6% weight loss. About 10–14% of people on the higher doses stopped because of side effects, versus about 5% on placebo.
Source: Lilly: retatrutide successful in two more phase 3 trials (July 2026) - May 2026
TRIUMPH-1 (2,339 adults with obesity): average weight loss at 80 weeks was 17.6% (4 mg), 23.7% (9 mg) and 25.0% (12 mg), versus 3.9% on placebo. People with severe obesity on the higher doses reached up to about 30% by 104 weeks.
Source: AJMC: retatrutide up to 30% weight loss in TRIUMPH-1 (May 2026) - Dec 2025
TRIUMPH-4 (knee osteoarthritis with obesity): the first phase 3 result, with large weight loss and less knee pain.
- Next
Lilly plans to apply for FDA approval in early 2027. Until then it is not approved anywhere.
HumanRead full profile →Tirzepatide
Approved medicineA once-a-week prescription injection that copies two gut hormones (GIP and GLP-1) to lower appetite and blood sugar.
- Studied for
- Approved for type 2 diabetes, chronic weight management and obstructive sleep apnea with obesity.
- Limits of the evidence
- Weight often returns after stopping. Stomach side effects are common, especially after dose increases.
- Approval
- FDA-approved (type 2 diabetes; chronic weight management)
Uses, latest studies & pairings
Typically used for
- Type 2 diabetes (Mounjaro).
- Chronic weight management, and moderate-to-severe obstructive sleep apnea with obesity (Zepbound).
- Also studied for heart failure with obesity, fatty liver and kidney disease.
Commonly paired with
- Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
- Not combined with other GLP-1 medicines: they work on the same receptors, so stacking adds side effects, not safety.
- Fiber, water and electrolytes to ease constipation and nausea.
- In diabetes, doctors may combine it with metformin, but insulin or sulfonylureas raise the risk of low blood sugar and often need lowering.
Latest studies & news
- 2026
Head-to-head (REDEFINE 4): tirzepatide averaged 25.5% weight loss versus 23.0% with CagriSema.
- 2025
SURMOUNT-5: tirzepatide beat semaglutide head-to-head, about 20% versus 14% average weight loss at 72 weeks.
- 2025
SURPASS-CVOT: in people with type 2 diabetes and heart disease, it was at least as good as dulaglutide (Trulicity) at preventing heart attacks, strokes and heart deaths.
HumanRead full profile →Semaglutide
Approved medicineA prescription GLP-1 medicine (weekly injection or daily tablet) that lowers appetite and blood sugar.
- Studied for
- Approved for type 2 diabetes, chronic weight management and lowering heart attack and stroke risk in people with heart disease and excess weight.
- Limits of the evidence
- Weight often returns after stopping. Stomach side effects are common; muscle needs protecting with training and protein.
- Approval
- FDA-approved (type 2 diabetes; chronic weight management)
Uses, latest studies & pairings
Typically used for
- Type 2 diabetes (Ozempic injection, Rybelsus tablet), including kidney protection in diabetic kidney disease.
- Weight management and lowering heart attack and stroke risk (Wegovy), plus a form of fatty liver disease with scarring (MASH).
- A once-a-day Wegovy pill was approved for weight management in December 2025.
Commonly paired with
- Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
- Not combined with other GLP-1 medicines: they work on the same receptors, so stacking adds side effects, not safety.
- Cagrilintide (an amylin medicine) in the investigational CagriSema combination.
- Fiber, water and electrolytes to ease stomach side effects.
Latest studies & news
- Dec 2025
Oral Wegovy (25 mg pill) approved in the US for weight management, based on trials averaging about 14% weight loss.
- Nov 2025
EVOKE trials: semaglutide did not slow early Alzheimer's disease.
- Aug 2025
Wegovy received accelerated approval for MASH with moderate-to-advanced liver scarring, after the ESSENCE trial: MASH resolved in about 63% of people versus 34% on placebo.
- 2025
Ozempic approved to lower kidney and heart risk in type 2 diabetes with chronic kidney disease (FLOW trial).
HumanRead full profile →Survodutide
InvestigationalAn experimental weekly injection that acts on both the GLP-1 and glucagon receptors.
- Studied for
- Obesity and fatty liver disease. In the 2026 SYNCHRONIZE-1 phase 3 trial, average weight loss reached up to 16.6% at 76 weeks.
- Limits of the evidence
- Not approved or filed yet. Stomach side effects were the most common, more so at higher doses.
- Approval
- Investigational; in Phase 3 development
Uses, latest studies & pairings
Typically used for
- Obesity and overweight.
- Fatty liver disease (MASLD and MASH with scarring), where its glucagon action on the liver may give it an edge.
Commonly paired with
- Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
- Not combined with other GLP-1 medicines: they work on the same receptors, so stacking adds side effects, not safety.
Latest studies & news
- Jun 2026
SYNCHRONIZE-1 (725 adults, 76 weeks): up to 16.6% average weight loss versus 3.2% on placebo. In a substudy, visceral (deep belly) fat fell by up to 34% and liver fat by up to 63%. Side effects were mostly stomach-related.
Source: PharmaTimes: survodutide delivers 16.6% weight loss in phase 3 (2026) - Jun 2026
SYNCHRONIZE-MASLD (218 people, 48 weeks) also met its main goals, published in Nature Medicine.
- 2024
Phase 2 MASH trial: up to 83% of people had their MASH improve, versus 18% on placebo.
- Next
LIVERAGE trials in MASH with scarring are due to report. Not yet filed for approval.
HumanRead full profile →CagriSema
InvestigationalAn experimental weekly combination of two medicines: semaglutide (GLP-1) and cagrilintide (an amylin-like hormone).
- Studied for
- Obesity and type 2 diabetes. In phase 3 (REDEFINE 1), average weight loss was about 20% over 68 weeks.
- Limits of the evidence
- Under FDA review (decision expected around late 2026). It fell short of tirzepatide head-to-head. Long-term data are limited.
- Approval
- Investigational; under FDA review, decision expected around late 2026
Uses, latest studies & pairings
Typically used for
- Obesity and overweight.
- Type 2 diabetes with obesity.
Commonly paired with
- It is itself a pairing: semaglutide (GLP-1) plus cagrilintide (amylin) in one weekly shot.
- Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
- Because it contains semaglutide, it carries the GLP-1 thyroid caution (MTC and MEN 2).
Latest studies & news
- 2026
Under FDA review: Novo Nordisk filed in December 2025, and a decision is expected around the end of 2026. Not approved yet.
Source: Zacks: can CagriSema help Novo close the gap in obesity (2026) - 2026
REDEFINE 4, head-to-head with tirzepatide: 23.0% versus 25.5% weight loss, so it missed its goal of matching tirzepatide.
- 2025
REDEFINE 1 (68 weeks): about 20% average weight loss versus 3% on placebo. REDEFINE 2 (type 2 diabetes): about 14% versus 3%.
HumanRead full profile →Eloralintide
InvestigationalAn experimental weekly injection that copies amylin, a hormone that helps you feel full.
- Studied for
- Obesity, as a weekly amylin medicine. In a 2025 phase 2 trial, the top dose averaged up to 20% weight loss at 48 weeks.
- Limits of the evidence
- Not approved; phase 3 is starting. Nausea and tiredness were common. Long-term safety unknown.
- Approval
- Investigational; phase 3 trials starting
Uses, latest studies & pairings
Typically used for
- Obesity and overweight (investigational).
- Lilly sees it as a possible option on its own or alongside other weight medicines for people who need more weight loss.
Commonly paired with
- Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
- As an amylin medicine, it isn't expected to carry the GLP-1 thyroid warning, but its long-term safety is still unknown.
Latest studies & news
- Nov 2025
Phase 2 (263 adults, 48 weeks, published in The Lancet): up to 20.1% average weight loss on the top dose versus 0.4% on placebo. Nausea (up to 64%) and tiredness were the most common side effects, and were lower with a slower step-up.
Source: Healio: amylin agonist eloralintide induces meaningful weight loss (2025) - Next
Lilly planned to start phase 3 trials at the end of 2025. Not approved.
HumanRead full profile →
Endocrine
Tesamorelin
Approved medicineA prescription injection that tells your pituitary gland to release more of your own growth hormone.
- Studied for
- Approved only to reduce excess belly fat in people with HIV-associated lipodystrophy.
- Limits of the evidence
- Not approved for general weight loss or anti-aging. It raises IGF-1 and can affect blood sugar.
- Approval
- FDA-approved for one indication (HIV-associated lipodystrophy)
Uses, latest studies & pairings
Typically used for
- Approved: reducing excess deep belly (visceral) fat in adults with HIV and lipodystrophy (Egrifta).
- Studied: fatty liver in people with HIV, where it lowered liver fat.
- Off-label, some clinics prescribe it for visceral fat or to raise growth hormone. That use isn't approved.
Commonly paired with
- Clinics often pair it with ipamorelin or CJC-1295 (other growth-hormone boosters). That combination hasn't been studied in trials, and stacking raises IGF-1 further.
- IGF-1 and blood sugar (glucose and HbA1c) checks, because it can raise both.
Latest studies & news
- Mar 2025
FDA approved Egrifta WR, a new formulation that is mixed once a week instead of daily (still a daily injection) and uses less than half the volume.
Source: Theratechnologies: FDA approval of Egrifta WR (March 2025)
HumanRead full profile →
Mitochondrial
MOTS-c
Not approvedA tiny peptide made by your own mitochondria that seems to act like an “exercise signal” in animals.
- Studied for
- Metabolism, insulin sensitivity and exercise capacity, mainly in mice and cells.
- Limits of the evidence
- Almost no human trial data. Safe and effective human doses are unknown.
- Approval
- Not an approved medicine; early-stage research
Uses, latest studies & pairings
Typically used for
- Marketed for fat loss, energy, insulin sensitivity and exercise capacity.
- Not approved for any use; the evidence is mainly from mice.
Commonly paired with
- Often marketed alongside exercise, NAD+ or GLP-1 medicines. None of these combinations has been studied.
Latest studies & news
- Jul 2026
An FDA advisory committee voted 7–5 to recommend letting pharmacies compound MOTS-c. This is not binding and isn't a finding that it works; the FDA hasn't made a final decision.
Source: Healio: FDA committee recommends looser restrictions for several peptides (July 2026) - 2026
A phase 2a trial testing MOTS-c for insulin sensitivity in adults with prediabetes and overweight began in 2026. No results yet.
- Earlier
A modified version (CB4211) was safe in a small phase 1b trial, but its development stopped.
AnimalRead full profile →SS-31 / Elamipretide
Approved medicineA small peptide that sticks to the inner wall of mitochondria to help them make energy with less damage.
- Studied for
- Mitochondrial disease. Approved (accelerated approval) only for Barth syndrome.
- Limits of the evidence
- Results in other conditions have been mixed, including a missed main goal in a mitochondrial myopathy trial. Not approved for energy or anti-aging.
- Approval
- FDA accelerated approval for Barth syndrome only
Uses, latest studies & pairings
Typically used for
- Approved: Barth syndrome, a rare inherited heart and muscle disease, in people weighing at least 30 kg (Forzinity).
- Studied: mitochondrial myopathy, heart failure and eye disease, with mixed or negative results.
- Sold online for energy and anti-aging, which is unapproved and unstudied.
Commonly paired with
- Often marketed with MOTS-c, NAD+ or urolithin A for “mitochondrial” stacks. None of these combinations has been studied.
Latest studies & news
- Sep 2025
FDA accelerated approval as Forzinity, the first Barth syndrome treatment, based on better knee-muscle strength. A confirmatory trial is required to keep the approval.
Source: FDA: accelerated approval for first treatment for Barth syndrome (2025)
HumanRead full profile →Urolithin A
Dietary supplementA compound your gut makes from pomegranates, berries and walnuts that helps your cells clear out old, worn-out mitochondria.
- Studied for
- Mitochondrial health and muscle endurance in older and middle-aged adults (randomized trials).
- Limits of the evidence
- Effects were modest, trials were small and several were company-funded.
- Approval
- Sold as a dietary supplement; not a drug
Uses, latest studies & pairings
Typically used for
- Healthy aging, muscle endurance and mitochondrial health (dietary supplement, e.g. Mitopure).
- Your gut makes it from pomegranates, berries and walnuts, but only about a third of people make much.
Commonly paired with
- Exercise (the trials that showed benefits measured muscle function), protein and creatine.
- Pomegranate, berries and walnuts as food sources.
Latest studies & news
- 2026
A JAMA Network Open trial tested urolithin A on blood-vessel and brain blood-flow function in middle-aged adults with obesity.
- 2022
Two 4-month randomized trials: better muscle endurance in older adults, and better strength in middle-aged adults (both modest).
HumanRead full profile →ATX-304
InvestigationalAn experimental drug (formerly called O304) that turns on AMPK, the body's “low fuel” sensor that exercise also switches on.
- Studied for
- Obesity and metabolism (AMPK activator). A small 2018 phase 2a human trial; muscle-preservation results with semaglutide so far are in mice.
- Limits of the evidence
- Not approved. Human data are early and small; don't read the mouse results as proven human benefits.
- Approval
- Investigational drug; not approved
Uses, latest studies & pairings
Typically used for
- Obesity and metabolism (investigational oral drug).
- Being explored as a partner to GLP-1 medicines to keep muscle and limit weight regain.
Commonly paired with
- Semaglutide, in mouse studies only. No human combination results have been published.
Latest studies & news
- 2025
Mouse data (ENDO 2025, from the developer): with semaglutide, weight loss came mostly from fat, with lean mass kept, and less regain after stopping semaglutide. Not yet shown in people.
- 2025
JCI Insight: reduced fatty liver in mice.
HumanRead full profile →
Tissue research
GHK-Cu
Not approvedA copper-carrying peptide found naturally in your blood, best known as a skin-care ingredient.
- Studied for
- Skin repair and collagen in lab studies and small cosmetic (on-the-skin) studies.
- Limits of the evidence
- Injected use hasn't been tested in good human trials. Lab results may not happen in people.
- Approval
- Not an approved medicine; used in cosmetic products
Uses, latest studies & pairings
Typically used for
- Skin care: serums and creams for firmness, fine lines and repair (the best-supported use).
- Hair products for thinning hair.
- Injected versions are sold by clinics and online, but injection is unstudied and unapproved.
Commonly paired with
- In vendor blends with BPC-157 and TB-500 (GLOW) and with KPV (KLOW). The blends have never been studied.
- In skin care, often used with moisturizer and sunscreen. Some dermatologists suggest not applying it at the same time as strong acids or vitamin C serums.
Latest studies & news
- Jul 2026
The FDA's compounding advisory committee did not vote on GHK-Cu. Injectable GHK-Cu is on the list for a later meeting, expected by early 2027.
Source: Mintz: what the FDA advisory committee peptide votes do and don't mean (July 2026)
In-vitroRead full profile →BPC-157
Not approvedA lab-made peptide based on a stomach protein, popular online for healing but tested almost only in animals.
- Studied for
- Tendon, muscle and gut healing in animal studies.
- Limits of the evidence
- Almost no human studies. An FDA panel's 2026 compounding vote isn't final or proof it works. Banned in sport; product contents are unverified.
- Approval
- Not approved; on the WADA Prohibited List. Compounding status under FDA review (2026)
Uses, latest studies & pairings
Typically used for
- Marketed for tendon, ligament and muscle injuries, gut problems (ulcers, colitis) and faster recovery.
- Evidence is almost all from rats; it is banned in tested sport (WADA).
Commonly paired with
- TB-500 (the “Wolverine stack”) and the GLOW or KLOW blends. No combination has been studied in people.
- Its blood-vessel-growth effect is the reason for caution with any cancer history.
Latest studies & news
- Jul 2026
An FDA advisory committee voted 8–6 to recommend letting pharmacies compound BPC-157 for ulcerative colitis, even though FDA staff said there was a lack of evidence it works. This is not binding; the FDA hasn't made a final decision.
Source: RAPS: FDA advisory committee backs two controversial peptides (July 2026) - 2025
A systematic review (HSS Journal) found 36 studies, of which 35 were in animals or cells and only 1 in people.
- 2025
A tiny IV safety pilot in 2 people was published. That's far too small to judge safety, and there are still no good-quality human trials.
AnimalRead full profile →OS-01
Not approvedA skin-care peptide designed to calm “zombie” (senescent) skin cells that drive skin aging.
- Studied for
- Skin aging, as a topical (on-the-skin) cosmetic peptide.
- Limits of the evidence
- Small, company-run studies; topical only. Not a medicine.
- Approval
- Cosmetic skin-care ingredient; not an approved medicine
Uses, latest studies & pairings
Typically used for
- Topical skin care for skin aging (OneSkin products).
- Not injected; not a medicine.
Commonly paired with
- Daily sunscreen and moisturizer, the basics that do the most for skin aging.
Latest studies & news
- 2025
Small studies: an eye-area formula reduced signs of aging, and a 12-week pilot improved the skin barrier.
- 2024
Double-blind, vehicle-controlled trial: improved measures of skin aging.
HumanRead full profile →
Inflammation research
KPV
Not approvedA three-amino-acid fragment of a natural anti-inflammatory hormone (alpha-MSH).
- Studied for
- Gut inflammation (colitis) in mouse and cell studies.
- Limits of the evidence
- No meaningful human trials. Anti-inflammatory effects in people are unproven.
- Approval
- Not an approved medicine; preclinical research
Uses, latest studies & pairings
Typically used for
- Marketed for gut inflammation (colitis), skin inflammation and wound healing.
- Evidence is from mice and cells only.
Commonly paired with
- BPC-157 for the gut, and the KLOW blend (GHK-Cu, BPC-157, TB-500 and KPV). No combination has been studied in people.
Latest studies & news
- Jul 2026
An FDA advisory committee voted to recommend letting pharmacies compound KPV. Reports differ on the exact vote and use. This is not binding; the FDA hasn't made a final decision.
Source: Mintz: what the FDA advisory committee peptide votes do and don't mean (July 2026)
AnimalRead full profile →
Vendor blend
GLOW blend
Not approvedNot a single compound: a vendor-made mix of several unapproved peptides (often GHK-Cu, BPC-157 and TB-500) in one vial.
- Studied for
- Marketed for skin and healing (a blend of BPC-157, TB-500 and GHK-Cu).
- Limits of the evidence
- The blend has never been studied. Each ingredient has mostly animal or lab data.
- Approval
- Not approved; no published clinical studies of the combination
Uses, latest studies & pairings
Typically used for
- Marketed for skin, hair, healing and recovery.
- A mix of GHK-Cu, BPC-157 and TB-500 in one vial; the mix itself has never been tested.
Commonly paired with
- It is already a pairing of three unapproved peptides. Adding more (KPV makes it KLOW) multiplies the unknowns.
Latest studies & news
- Jul 2026
An FDA advisory committee voted 8–6 to recommend compounding TB-500 (for wound healing) and BPC-157, and postponed GHK-Cu. None of this covers blends, and it isn't final.
Source: Healio: FDA committee recommends looser restrictions for several peptides (July 2026)
InsufficientRead full profile →KLOW blend
Not approvedA vendor-made mix that adds KPV to the GLOW blend (GHK-Cu, BPC-157, TB-500).
- Studied for
- Marketed for healing and inflammation (GLOW plus KPV).
- Limits of the evidence
- The blend has never been studied. Each ingredient has mostly animal or lab data.
- Approval
- Not approved; no published clinical studies of the combination
Uses, latest studies & pairings
Typically used for
- Marketed for healing, gut and skin inflammation.
- GLOW plus KPV; the mix itself has never been tested.
Commonly paired with
- It is already a pairing of four unapproved peptides; dose, purity and interactions are unknown.
Latest studies & news
- Jul 2026
An FDA advisory committee recommended compounding several of its single ingredients (BPC-157, TB-500, KPV). That doesn't cover blends and isn't final.
Source: Healio: FDA committee recommends looser restrictions for several peptides (July 2026)
InsufficientRead full profile →
Evidence classification
Four tiers. No blurred lines.
01 · Green
Human clinical evidence
Data from studies in people, such as randomized controlled trials. Strength still depends on design, size, duration and endpoints.
02 · Blue
Animal research
Findings from animal models. Useful for generating hypotheses, but results frequently fail to translate to humans.
03 · Orange
Laboratory / in-vitro
Cell, tissue or biochemical experiments. They show what can happen in a controlled system, not what happens in a living person.
04 · Grey
Theoretical / insufficient
Mechanistic reasoning, anecdote or too little data to draw conclusions. Not evidence of effect.
Clinical trial updates
Recently updated registered trials
Live from ClinicalTrials.gov. A registered trial describes a study plan — it does not show that an intervention is effective.
NCT06274749
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
National Institute on Aging (NIA)
- Phase
- Phase n/a
- Status
- Recruiting
- Enrollment
- 180
- Est. completion
- Mar 31, 2027
NCT07840729
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Shanghai JMT-Bio Inc.
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 90
- Est. completion
- Apr 30, 2027
NCT07911046
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
Erin Mauney
- Phase
- Phase n/a
- Status
- Not Yet Recruiting
- Enrollment
- 12
- Est. completion
- Jun 2029
NCT07906041
Tirzepatide and Organ-specific Biological Aging
Atria Research and Global Health Institute (ARGHI)
- Phase
- Phase 2
- Status
- Enrolling By Invitation
- Enrollment
- 22
- Est. completion
- Sep 2028
NCT07908940
Changes in Body Composition Following Pharmacological Treatment for Obesity.
Hospital San Carlos, Madrid
- Phase
- Phase n/a
- Status
- Enrolling By Invitation
- Enrollment
- 116
- Est. completion
- Dec 31, 2027
NCT04916470
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Novo Nordisk A/S
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 617
- Est. completion
- Oct 11, 2023
Source: ClinicalTrials.gov API v2 · Last synchronized Nov 3, 2026
Scientific publications
Newly indexed in PubMed
Diabetology international · 2027 Jan
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes
Okuma H
PMID 42968811DOI 10.1007/s13340-026-00940-3
Appetite · 2027 Jan 1
Food noise: A theoretical review
Wylie F, Mahmut MK, Francis HM, et al.
PMID 42772688DOI 10.1016/j.appet.2026.108791
Bioactive materials · 2027 Jan
Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming
Li H, Zhang Y, Jian Y, et al.
PMID 42633281DOI 10.1016/j.bioactmat.2026.06.010
Lancet (London, England) · 2026 Dec 20
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al.
PMID 41207308DOI 10.1016/S0140-6736(25)01776-3
Indexing in PubMed is not an endorsement of a study's quality or conclusions.